Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

Orion bolsters cancer pipeline after insomnia drug setback
23 Oct 2025, 12:30ORNBV.HENASDAQ Helsinki

Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.

BlackRock cut its Orion stake before drug trial failed
30 Sept 2025, 10:00ORNBV.HENASDAQ Helsinki

Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.

Orion's cancer drug approval fuels major profit growth
21 Jul 2025, 07:31ORNBV.HENASDAQ Helsinki

Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.

Orion profit soars on blockbuster prostate cancer drug sales
18 Jul 2025, 09:01ORNBV.HENASDAQ Helsinki

Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.

Orion lifts 2025 outlook on strong cancer drug sales
9 Jul 2025, 10:01ORNBV.HENASDAQ Helsinki

Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.

Orion's blockbuster prostate drug gains key EU panel backing
20 Jun 2025, 17:45ORNBV.HENASDAQ Helsinki

A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Orion publishes 2008 Financial Statement release on 6 Feb 200919 Jan 2009
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 200816 Jan 2009
Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®15 Jan 2009
Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland7 Jan 2009
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States11 Dec 2008
Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®8 Dec 2008
Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland19 Nov 2008
Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®12 Nov 2008
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States3 Nov 2008
Composition of the Nomination Committee of Orion Corporation29 Oct 2008
Orion Group Interim Report 1-9/200828 Oct 2008
Orion Corporation's publication schedules for financial reporting in 200928 Oct 2008
  • Previous
  • 1
  • More pages
  • 73
Search
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
  • Next
  • 74
  • 75
  • More pages
  • 95
  • Next
  • Filings
    1,130